Test Directory

RUNX1::RUNX1T1 t(8:21)(q22;q22) Diagnostic (AML)

Containers - Adult

Red Cap Tube EDTA KE 9ml
Volume Range

10-15ml Peripheral blood or bone marrow specimen​

Additive per Container


Laboratory Site

Crewe Road South
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  Specimens should arrive no later than 3.30pm on Friday.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road


EH4 2XU​


See also Specimen transportation.

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

Please refer to our detailed requestinginstructions.  The HMDS request form can be located here.​ 


Testing may be performed by reflex from immunophenotyping.


Monday-Friday 9am-5pm

Anticipated turnaround

​Results for diagnostic samples should be expected within 3 working days.  See results.

What happens if the result is positive or abnormal

​The requesting clinician will be contacted where results are clinically significant. Please ensure details are included on request form.

Static information/disclaimer

This test is accredited to ISO 15189:2012

General additional information

​Full AML panel testing is performed on all patients <70 years old diagnosed with AML based on immunophenotyping results via a reflex testing strategy. 

Please see RUNX1::RUNX1T1 MRD monitoring for follow up samples

Approximately 5% of AML cases carry translocation which produces RUNX1::RUNX1T1 fusion gene. The RUNX1::RUNX1T1 fusion transcript usually arises as a result of the t(8;21)(q22;q22) chromosomal rearrangements. It is usually associated with a more favourable outcome within AML. A diagnosis of AML is considered in cases where RUNX1::RUNX1T1 rearrangement is detected regardless of the blast cell count.

RUNX1::RUNX1T1 fusion gene analysis is carried out as part of the AML testing panel, which also includes BCR::ABL1, CBFB::MYH11, PML::RARA, KMT2A fusion gene, FLT3 (ITD and D835) and NPM1 gene mutation analysis.

The KIT mutation occurs in approximately 16-46% of patients and adversely affects prognosis.  Patients who are identified as having RUNX1::RUNX1T1 fusion gene are tested for the presence of a KIT D816V mutation.

For clinical advice on appropriate investigations and advice for the interpretation of test results, please contact us​.